P1005: Comparative short-term effectiveness of tofacitinib and upadacitinib in refractory, moderate-to-severe ulcerative colitis – An international, multicenter cohort studyECCO'25Year: 2025
Authors: Farkas, B.(1)*;Resál, T.(2);Lakatos, P.L.(3);Limdi, J.K.(4);Armuzzi, A.(5);Bezzio, C.(5);Savarino, E.V.(6);Saibeni, S.(7);Michalopoulos, G.(8);Attauabi, M.(9);Seidelin, J.B.(9);Fousekis, F.S.(10);Katsanos, K.(10);Bacsur, P.(1);Ivány, E.(1);Bálint, A.(1);Szepes, Z.(1);Farkas, K.(1);Molnár, T.(1);
(1)University of Szeged, Center for Gastroenterology, Szeged, Hungary;(2)HCEMM-USZ, Translational Colorectal Research Group, Szeged, Hungary;(3)McGill University Health Centre, Division of Gastroenterology, Montreal, Canada;(4)Northern Care Alliance NHS Foundation Trust, IBD Unit, Manchester, United Kingdom;(5)IRCCS Humanitas Research Hospital, IBD Center, Milan, Italy;(6)Azienda Ospedale Università of Padua, Gastroenterology Unit, Padua, Italy;(7)Rho Hospital- ASST Rhodense, Gastroenterology Unit, Milan, Italy;(8)General Hospital of Athens "G. Gennimatas", Gastroenterology, Athens, Greece;(9)Copenhagen University Hospital - Herlev and Gentofte, Department of Gastroenterology and Hepatology, Herlev, Denmark;(10)University Hospital of Ioannina, Division of Gastroenterology, Ioannina, Greece;
P1006: Effectiveness of Upadacitinib in Patients with Baseline Active Extraintestinal Manifestations and Inflammatory Bowel Disease. A multicenter retrospective studyECCO'25Year: 2025
Authors: Fuentes-Valenzuela, E.(1)*;Chivato Martín-Falquina, I.(2);Caballero-Mateos, A.M.(3);Botella Mateu, B.(4);Fernández-Prada, S.(5);Calvo Moya, M.(6);Rubín de Célix, C.(7);Olmedo Moreno, C.(8);Suarez Ferrer, C.(9);Iborra, M.(10);Carballo-Folgoso, L.(11);Barrero, S.(7);Martín-Arranz, M.D.(9);Rafael de la Cruz Esteban, D.(8); Yagüe, C.(12);García , M.J.(13);Saiz-Chumillas, R.M.(14);Sicilia, B.(15);Segarra-Ortega, J.X.(16);Ruíz Ramírez, M.Á.(17);García de la Filia, I.(18);Betoré Glaría, E.(19);Andreo Vidal, B.E.(16);Velayo, B.(20);López-Martín, M.D.C.(2);Calvache Rodríguez, A.(2);Gil Santana, M.(2);Barrio, J.(5);
(1)Hospital Universitario Infanta Elena, Gastroenterology Department, Madrid, Spain;(2)Hospital Universitario Infanta Elena, Gastroenterology Department., Madrid, Spain;(3)Hospital Santa Ana, Gastroenterology Department., Motril, Spain;(4)Puerta de Hierro University Hospital, Inflammatory Bowel Disease Unit-, Majadahonda, Spain;(5)Hospital Universitario Rio Hortega, Gastroenterology Department., Valladolid, Spain;(6)Puerta de Hierro University Hospital, Inflammatory Bowel Disease Unit, Majadahonda, Spain;(7)Hospital Universitario de Fuenlabrada, Gastroenterology Department., Fuenlabrada, Spain;(8)Hospital Universitario 12 de Octubre, Gastroenterology Department., Madrid, Spain;(9)Hospital Universitario La Paz. IDIPaz., Gastroenterology Department., Madrid, Spain;(10)Hospital Universitario La Fe, Gastroenterology Department., Valencia, Spain;(11)Hospital Universitario Central de Asturias, Gastroenterology Department., Oviedo, Spain;(12)Hospital Universitario Miguel Servet, Gastroenterology Department., Zaragoza, Spain;(13)Hospital Universitario Marqués de Valdecilla- IDIVAL., Gastroenterology and Hepatology Department., Santander, Spain;(14)Hospital General de Almansa, Gastroenterology Department., Almansa, Spain;(15)Hospital Universitario de Burgos, Gastroenterology Department., Burgos, Spain;(16)Hospital Universitario de Salamanca, Gastroenterology Department., Salamanca, Spain;(17)Hospital universitario de Albacete, Gastroenterology Department., Albacete, Spain;(18)Hospital Universitario Ramón y Cajal, Gastroenterology Department., Madrid, Spain;(19)Hospital Universitario San Jorge, Gastroenterology Department., Huesca, Spain;(20)Hospital Clínico Universitario de Valladolid, Gastroenterology Department., Valladolid, Spain;
P1007: Influence of pharmacokinetic-pharmacodynamic failure mechanisms on outcomes in biologic therapy sequencing in inflammatory bowel diseaseECCO'25Year: 2025
Authors: Steenholdt, C.(1,2)*;Lorentsen, R.D.(3);Henneberg, J.(1);Petersen, P.(1);Brynskov, J.(1);
(1)Herlev Hospital, Department of Gastroenterology, Herlev, Denmark;(2)Odense University Hospital, Department of Medical Gastroenterology, Odense, Denmark;(3)North Zealand Hospital, Department of Medical Gastroenterology, Hillerød, Denmark;
P1008: Subcutaneous infliximab in IBD patients previously treated with an optimized intravenous infliximab dosing schedule: preliminary results on expectations and satisfaction of switching from intravenous to subcutaneous infliximab.ECCO'25Year: 2025
Authors: Moens, A.(1)*;Holvoet, T.(2);Bossuyt, P.(3);Lobaton, T.(4);Posen, A.(5);Cremer, A.(6);Capirchio, L.(7);Caenepeel, C.(8);Lambrecht, G.(9);Amezaga, A.J.(10);Reenaers, C.(11);Peeters, H.(12);Willandt, B.(13);Deprez, N.(14);De Rechter, J.(15);Arijs, I.(15);Straetemans, N.(5);Dreesen, E.(16);Ferrante, M.(17);
(1)Heilig Hartziekenhuis Lier, Department of Gastroenterology, Lier, Belgium;(2)VITAZ, Department of Gastroenterology and Hepatology, Sint-Niklaas, Belgium;(3)Imelda General Hospital, Imelda GI Clinical Research Center- Department of Gastroenterology, Bonheiden, Belgium;(4)University Hospital Ghent, Department of Gastroenterology and Hepatology, Ghent, Belgium;(5)AZ Vesalius, Department of Gastroenterology, Tongeren, Belgium;(6)Erasme University Hospital, Department of Gastroenterology, Brussels, Belgium;(7)CHwapi, Department of Gastroenterology, Tournai, Belgium;(8)Ziekenhuis Oost-Limburg, Department of Gastroenterology, Genk, Belgium;(9)AZ Oostende, Department of Gastroenterology, Oostende, Belgium;(10)University hospital Antwerp, Department of Gastroenterology and Hepatology, Antwerp, Belgium;(11)CHU Sart Tilman, Department of Gastroenterology, Liège, Belgium;(12)AZ Sint-Lucas Gent, Department of Gastroenterology, Ghent, Belgium;(13)AZ Sint-Jan Brugge, Department of Gastroenterology, Bruges, Belgium;(14)AZ Maria Middelares, Department of Gastroenterology, Ghent, Belgium;(15)Belgian IBD Research and Development BIRD, Office, Zaventem, Belgium;(16)KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium;(17)University Hospitals Leuven- KU Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium; Belgian IBD Research and Development (BIRD)
P1009: Enhancing Inflammatory Bowel Disease care: The role of mobile applications in disease managementECCO'25Year: 2025
Authors: Telli, P.(1)*;Çavuş, B.(1);Çifcibaşı Örmeci, A.(1);Kalkan, İ.H.(2);Karakan, T.(3);Arhan, M.(2);Törüner, M.(4);Akyüz, F.(1);
(1)Istanbul University- Istanbul Faculty of Medicine, Gastroenterology and Hepatology, Istanbul, Turkey;(2)TOBB ETÜ Hospital, Gastroenterology and Hepatology, Ankara, Turkey;(3)Gazi University Faculty of Medicine, Gastroenterology and Hepatology, Ankara, Turkey;(4)Ankara University Faculty of Medicine, Gastroenterology and Hepatology, Ankara, Turkey;
Wang R, Li Z, Liu S, Zhang D. Global, regional and national burden of inflammatory bowel disease in 204 countries and territories from 1990 to 2019: a systematic analysis based on the Global Burden of Disease Study 2019. BMJ open. 2023;13(3):e065186.
P1011: Correlations of clinical characteristics and serum proteins with drug levels: A multicentre cohort study of patients with inflammatory bowel disease starting biologicsECCO'25Year: 2025
Authors: Visuri, I.(1);Dannenberg, K.(2);Salomon, B.(2);Ling Lundström, M.(3);Bergemalm, D.(1)*;Eriksson, C.(1,4);Lindqvist, M.(2);Keita, Å.V.(5);Magnusson, M.K.(6);D'Amato, M.(7,8,9,10);Hjortswang, H.(11);Strid, H.(12);Söderholm, J.D.(5,13);Öhman, L.(6);Carlson, M.(3);Kruse, R.(2);Hedin, C.R.H.(14,15);Repsilber, D.(2);Halfvarson, J.(1);
(1)Örebro University, Department of Gastroenterology- Faculty of Medicine and Health, Örebro, Sweden;(2)Örebro University, School of Medical Sciences, Örebro, Sweden;(3)Uppsala University, Department of Medical Sciences- Gastroenterology Research Group, Uppsala, Sweden;(4)Karolinska Institutet, Clinical Epidemiology Division- Department of Medicine Solna, Stockholm, Sweden;(5)Linköping University, Department of Biomedical and Clinical Sciences, Linköping, Sweden;(6)University of Gothenburg, Department of Microbiology and Immunology- Institute of Biomedicine, Gothenburg, Sweden;(7)Karolinska Institute, Clinical Epidemiology Unit- Department of Medicine, Solna, Sweden;(8)Ikerbasque, Basque Foundation for Science, Bilbao, Spain;(9)CIC BioGUNE–BRTA, Gastrointestinal Genetics Lab, Derio, Spain;(10)LUM University, Department of Medicine and Surgery, Casamassima, Italy;(11)Linköping University, Division of Gastroenterology and Hepatology- Department of Clinical and Experimental Science, Linköping, Sweden;(12)Södra Älvsborg Hospital, Department of Internal Medicine, Borås, Sweden;(13)Linköping University, Department of Surgery, Linköping, Sweden;(14)Karolinska Institute, Department of Medicine Solna, Stockholm, Sweden;(15)Karolinska University Hospital, Centre for Digestive Health- Department of Gastroenterology- Dermatovenereology and Rheumatology, Stockholm, Sweden; BIOIBD consortium
P1012: Systemic biologic therapies are associated with comparable safety outcomes to vedolizumab for the management of Inflammatory Bowel Disease following liver transplantationECCO'25Year: 2025
Authors: Chin, S.(1,2)*;Con, D.(1);Hilley, P.(1);Corte, C.(2);Testro, A.(1);De Cruz, P.(1);Choy, M.(1);Srinivasan, A.(1);
(1)Austin Health, Gastroenterology, Melbourne, Australia;(2)Royal Prince Alfred Hospital, AW Morrow Gastroenterology and Hepatology, Sydney, Australia;
P1013: Adverse Events of Methotrexate in Paediatric Inflammatory Bowel Disease: A Retrospective Cohort StudyECCO'25Year: 2025
Authors: Vermeer, E.(1)*;Soetens, E.L.(1);Struys, E.A.(2);de Boer, N.K.H.(3);de Jonge, R.(2);de Meij, T.G.J.(1);
(1)Amsterdam UMC, Department of Paediatric Gastroenterology, Amsterdam, The Netherlands;(2)Amsterdam UMC, Department of Laboratory Medicine, Amsterdam, The Netherlands;(3)Amsterdam UMC, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;
P1014: Anti-TNF-alpha biosimilar cross and reverse-switching in pediatric IBD: Preliminary real-world data from the SIGENP IBD Working GroupECCO'25Year: 2025
Authors: Dipasquale, V.(1)*;Fioretti, L.(2);Morello, R.(3);Pochesci, S.(2);Scarallo, L.(2);Graziano, F.(4);Citrano, M.(4);Lionetti, P.(2);Romano, C.(3);
(1)University Hospital of Messina, Department of Human Pathology in Adulthood and Childhood "G. Barresi", Messina, Italy;(2)Meyer Children's Hospital, Gastroenterology and Nutrition Unit, Florence, Italy;(3)University Hospital “G. Martino”, Pediatric Gastroenterology and Cystic Fibrosis Unit, Messina, Italy;(4)Villa Sofia Cervello Hospital, Pediatric Unit, Palermo, Italy;
de Ridder L, Assa A, Bronsky J, et al. Use of biosimilars in pediatric inflammatory bowel disease: an updated position statement of the pediatric IBD Porto Group of ESPGHAN. J Pediatr Gastroenterol Nutr. 2019;68:144–153. doi:10.1097/MPG.0000000000002141
Mysler, E., Azevedo, V.F., Danese, S. et al. Biosimilar-to-biosimilar switching: what is the rationale and current experience?. Drugs 81, 1859–1879 (2021). https://doi.org/10.1007/s40265-021-01610-1
Cohen, H.P., Hachaichi, S., Bodenmueller, W. et al. Switching from one biosimilar to another biosimilar of the same reference biologic: a systematic review of studies. BioDrugs 36, 625–637 (2022). https://doi.org/10.1007/s40259-022-00546-6
Dipasquale V, Pellegrino S, Ventimiglia M, Cucinotta U, Citrano M, Graziano F, Cappello M, Busacca A, Orlando A, Accomando S, Romano C; Sicilian Network for Inflammatory Bowel Disease. Real-life experience of infliximab biosimilar in pediatric-onset inflammatory bowel disease: data from the Sicilian Network for Inflammatory Bowel Disease. Eur J Gastroenterol Hepatol. 2022 Oct 1;34(10):1007-1014. doi: 10.1097/MEG.0000000000002408
Dipasquale V, Pellegrino S, Ventimiglia M, Citrano M, Graziano F, Cappello M, Busacca A, Orlando A, Accomando S, Romano R; Sicilian Network for Inflammatory Bowel Disease. Adalimumab biosimilar in pediatric inflammatory bowel disease: a retrospective study from the Sicilian Network for Inflammatory Bowel Disease (SN-IBD). Healthcare (Basel). 2024 Feb 4;12(3):404. doi: 10.3390/healthcare12030404
Dipasquale V, Cicala G, Spina E, Romano C. Biosimilars in Pediatric Inflammatory Bowel Diseases: A Systematic Review and Real Life-Based Evidence. Front Pharmacol. 2022 Mar 17;13:846151. doi: 10.3389/fphar.2022.846151
P1016: Leishmaniasis in patients with inflammatory bowel disease: a national multicenter study of GETECCUECCO'25Year: 2025
Authors: Madero Velázquez, L.(1)*;Minguez, A.(2);Mayorga, L.(3);Ramírez, J.J.(4);Moreno, N.(5);Amorós, C.(6);Nicolás, I.(7);Mena, R.(8);Benitez, J.M.(9);Gimeno, L.(10);Maroto, N.(11);Suria, C.(12);Rodriguez-Moranta, F.(13);Ordás, I.(14);Ruiz, L.(15);García-Brenes , M.A.(16);Martín, A.(17);Rubín, C.(18);Cárdenas, K.(19);Ginard, D.(20);Medina, L.(21);Pedrero, N.(22);Plaza, R.(23);Salmoral, R.(24);Martínez, T.(25);Algara, V.(26);Merino, E.(27);Zabana, Y.(28);Gutierrez Casbas, A.(29);
(1)Hospital General Universitario Dr. Balmis- Alicante. ISABIAL., Gastroenterology, Alicante, Spain;(2)Hospital Universitario y Politécnico La Fe- Valencia. CIBERehd, Gastroenterology, Valencia, Spain;(3)Hospital Universitario Valle de Hebrón- Barcelona, Gastroenterology, Barcelona, Spain;(4)Hospital Lluis Alcanys de Xativa- Valencia, Gastroenterology, Valencia, Spain;(5)Hospital Universitario Dr Peset- Valencia., Gastroenterology, Valencia, Spain;(6)Hospital Arnau de Vilanova- Valencia-, Gastroenterology, Valencia, Spain;(7)Hospital Universitario Reina Sofia de Murcia, Gastroenterology, Murcia, Spain;(8)Consorci Sanitari de Terrasa, Gastroenterology, Terrasa, Spain;(9)Hospital Universitario Reina Sofía- IMIBIC- Córdoba- Spain, Gastroenterology, Córdoba, Spain;(10)Hospital General Universitario de Castellón, Gastroenterology, Castellón, Spain;(11)Hospital de Manises- Valencia, Gastroenterology, Valencia, Spain;(12)Hospital Clínico de Valencia, Gastroenterology, Valencia, Spain;(13)Hospital Universitario de Bellvitge- Barcelona, Gastroenterology, Barcelona, Spain;(14)Hospital Clínic- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD- Institut d’Investigacions BiomèdiquesAgustí Pi i Sunyer IDIBAPS-Barcelona- Spain, Gastroenterology, Barcelona, Spain;(15)Consorcio Hospital General Universitario de València., Gastroenterology, Valencia, Spain;(16)Hospital Clínico San Carlos de Madrid, Gastroenterology, Madrid, Spain;(17)Hospital Universitari Mútua Terrassa- University of Barcelona- Terrassa- Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBERehd- Instituto de Salud Carlos III- Madrid- Spain., Gastroenterology, Terrasa, Spain;(18)Hospital Universitario de La Princesa- Instituto de Investigación Sanitaria Princesa IIS-Princesa- Universidad Autónoma de Madrid UAM- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD- Madrid- Spain, Gastroenterology, Madrid, Spain;(19)Hospital Virgen de los Lirios de Alcoy- Alicante- Spain, Gastroenterology, Alicante, Spain;(20)Hospital Universitario Son Espasses- Mallorca, Gastroenterology, Mallorca, Spain;(21)Hospital Marina Baixa- Villajoyosa- Spain, Gastroenterology, Alicante, Spain;(22)Hospital General Universitario Santa Lucía- Cartagena- Spain., Gastroenterology, Murcia, Spain;(23)Hospital Universitario Infanta Leonor de Madrid, Gastroenterology, Madrid, Spain;(24)Hospital General Universitario de Toledo, Gastroenterology, Toledo, Spain;(25)Hospital Universitario de Cuenca- Spain, Gastroenterology, Cuenca, Spain;(26)Hospital Universitario del Vinalopó- Elche- Spain, Gastroenterology, Elche, Spain;(27)Hospital General Universitario Dr Balmis de Alicante- Instituto de Investigación Sanitaria y Biomédica de Alicante ISABIAL- Alicante- Spain., Infectious Diseases Department-, Alicante, Spain;(28)Hospital Universitari Mútua Terrassa- University of Barcelona- Terrassa- Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBERehd- Instituto de Salud Carlos III- Madrid- Spain., Gastroenterology, Barcelona, Spain;(29)Hospital General Universitario Dr Balmis de Alicante- Instituto de Investigación Sanitaria y Biomédica de Alicante ISABIAL- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD- Alicante- Spain., Gastroenterology, Alicante, Spain;
1. Kirchgesner J, Lemaitre M, Carrat F, Zureik M, Carbonnel F, Dray-Spira R. Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases. Gastroenterology. 2018 Aug;155(2):337-346.
2. Kucharzik T, Ellul P, Greuter T, Rahier JF, Verstockt B, Abreu C, et al. ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease. J Crohns Colitis. 2021 Jun 22;15(6):879-913. doi: 10.1093/ecco-jcc/jjab052. Erratum in: J Crohns Colitis. 2023 Jan 27;17(1):149.
3. Kirchgesner J, Lemaitre M, Carrat F, Zureik M, Carbonnel F, Dray-Spira R. Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases. Gastroenterology. 2018 Aug;155(2):337-346.
P1017: Real-world effectiveness and safety of filgotinib with and without concomitant therapies in patients with Ulcerative Colitis: an interim analysis of the prospective, observational GALOCEAN studyECCO'25Year: 2025
Authors: HøivikMD- PhD, M.(1,2)*;Vermeire, S.(3);Reinisch, W.(4);Seenan, J.P.(5);Löwenberg, M.(6);Schreiber, S.(7);Armuzzi, A.(8,9);Ricart, E.(10,11);Doherty, G.(12);Saldaña, R.(13);Sawyer, W.(14);Rudolph, C.(15);Jus, A.(16);Gilletta de Saint Joseph, C.(17);
(1)Oslo University Hospital, Department of Gastroenterology, Oslo, Norway;(2)University of Oslo, Institute of Clinical Medicine, Oslo, Norway;(3)UZ Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(4)Medical University of Vienna, Division of Gastroenterology and Hepatology, Vienna, Austria;(5)Queen Elizabeth University Hospital, Department of Gastroenterology, Glasgow, United Kingdom;(6)Amsterdam UMC- University of Amsterdam, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(7)Kiel University- University Hospital Schleswig-Holstein, Department of Internal Medicine I, Kiel, Germany;(8)IRCCS Humanitas Research Hospital- Rozzano, Inflammatory Bowel Disease Center, Milan, Italy;(9)Humanitas University- Pieve Emanuele, Department of Biomedical Sciences, Milan, Italy;(10)Hospital Clínic- Institut d'Investigacions Biomèdiques August Pi i Sunyer IDIBAPS, Gastroenterology Department, Barcelona, Spain;(11)Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, Gastroenterology Department, Madrid, Spain;(12)St Vincent’s University Hospital and School of Medicine- University College Dublin, Centre for Colorectal Disease, Dublin, Ireland;(13)European Federation of Crohn's and Colitis Associations EFCCA, Innovation and Patient Engagement, Brussels, Belgium;(14)Alfasigma S.p.A., Biostatistics, Bologna, Italy;(15)Alfasigma S.p.A., Medical Director Gastroenterology- Specialty Care- Global Medical Affairs, Bologna, Italy;(16)Alfasigma S.p.A., Evidence Generation- Global Medical Affairs, Bologna, Italy;(17)Centre Hospitalier Universitaire de Toulouse, Gastroenterology and Pancreatology Department, Toulouse, France;
1. Feagan BG et al. Lancet 2021;397:2372–84.
P1018: Diyushengbai tablets alleviate azathioprine-induced leukopenia in patients with Crohn's DiseaseECCO'25Year: 2025
Authors: Zeng, Z.(1)*;Yuan, J.(1);Zhang, H.(1);
(1)West China Hospital of Sichuan University, Department of Gastroenterology, Chengdu, China;
P1019: Role of Oncostatin M (Osm)-Osmr signaling in colonic inflammation and host defense during citrobacter rodentium infectionECCO'25Year: 2025
Authors: Luo, Y.(1,2)*;Cineus, R.(1,2);Bösel, D.(1,2);Cancino, C.(1,2);Blazquez, L.V.(1,2);Konopka, A.(1,2);Hegazy, A.N.(1,2);
(1)Charité-Universitätsmedizin- Berlin, Department of Gastroenterology- Infectious Diseases and Rheumatology, Berlin, Germany;(2)Deutsches Rheumaforschungszentrum Berlin DRFZ, An Institute of the Leibniz Association, Berlin, Germany;
P1020: Trends in Opioid Use among Patients with Inflammatory Bowel Disease and Changes Following Advanced Therapy Initiation: A Korean nationwide population-based studyECCO'25Year: 2025
Authors: Jun, Y.K.(1)*;Ji, E.(2);Choi, Y.(3);Shin, C.M.(3);Park, Y.S.(3);Kim, N.(3);Lee, D.H.(3);Yoon, H.(3);
(1)Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam- Gyeonggi-do, Korea- Republic Of;(2)Seoul National University Bundang Hospital, Medical Research Collaborating Center, Seongnam- Gyeonggi-do, Korea- Republic Of;(3)Seoul National University Bundang Hospital, Department of Internal Medicine, Seongnam- Gyeonggi-do, Korea- Republic Of;
P1021: Treatment Patterns for Crohn’s Disease: a Multinational Analysis from 2011 to 2022 in the United States, Japan, and ChinaECCO'25Year: 2025
Authors: Yan, L.(1)*;Xu, Y.(1);Gao, J.(2);Wu, T.(1);Chung, H.(3);Jiang, K.(2);Suruki, R.(3);Zhang, Y.(1);Liang, J.(2);Qiu, H.(3);Wu, K.(2);
(1)Janssen Research & Development, Global Epidemiology, Shanghai, China;(2)Xijing Hospital of Digestive Diseases- Fourth Military Medical University, State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and National Clinical Research Center for Digestive Diseases, Xi'an, China;(3)Janssen Research & Development, Global Epidemiology, Titusville, United States;
Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG Clinical Guideline: Management of Crohn's Disease in Adults. The American Journal of Gastroenterology. 2018;113(4):481-517.
Gordon H, Minozzi S, Kopylov U, Verstockt B, Chaparro M, Buskens C, et al. ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. Journal of Crohn's and Colitis. 2024.
Nakase H, Uchino M, Shinzaki S, Matsuura M, Matsuoka K, Kobayashi T, et al. Evidence-based Clinical Practice Guidelines for Inflammatory Bowel Disease 2020. Journal of Gastroenterology. 2021;56(6):489-526.
Chen M, Wu K, Ji Y. 2023 Chinese National Clinical Practice Guideline on Diagnosis and Management of Crohn’s disease. Chinese Medical Journal. 2024;137(14):1647-50.
P1022: ChatGPT in the management of Inflammatory Bowel Disease, a future or a present reality?ECCO'25Year: 2025
Authors: Aillaud, D.(1,2)*;Acosta, E.(1);Hernández, L.(1);Marines, D.(1);Manzano, H.(3);
(1)Houston Methodist Willowbrook Hospital, Division of Colon and Rectal Surgery, Houston, United States;(2)Harvard Medical School, Center for Bioethics, Boston, United States;(3)Hospital Ángeles Puebla, Gastroenterology and Hepatology, Puebla, Mexico;
1. Raine T, Bonovas S, Burisch J, et al. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. J Crohns Colitis. 2022;16(1):2-17. doi:10.1093/ecco-jcc/jjab178 2. Torres J, Bonovas S, Doherty G, et al. ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment. J Crohns Colitis. 2020;14(1):4-22. doi:10.1093/ecco-jcc/jjz180
P1023: Clinical study of composite sophora colon-soluble capsules combined with vedolizumab in the treatment of Ulcerative ColitisECCO'25Year: 2025
Authors: Li , X.(1)*;Xie , Y.(2);Tian , F.(3);
(1)Gastroenterology department, China Medical University of Shengjing Hospital, Shenyang, China;(2)Shengjing Hospital of China Medical University, Department of Gastroenterology, Shenyang , Liaoning Province, China;(3)Shengjing Hospital of China Medical University, Department of Gastroenterology, Shenyang , Liaoning Province, China;
P1024: Switching to subcutaneous infliximab in week 6 – the effect on mucosal healing and treatment persistenceECCO'25Year: 2025
Authors: Brinar, M.(1)*;Zlopasa, L.(1);Kodvanj, I.(1);Jelakovic , M.(1);Turk , N.(1);Grgic, D.(1);Cukovic Cavka, S.(1);Kunovic, A.(1);Krznaric , Z.(1);
(1)University Hospital Centre Zagreb, Department of Gastroenterology and Hepatology, Zagreb, Croatia;
P1025: A mental health intervention can support increased capacity and revenue in the IBD outpatient setting.ECCO'25Year: 2025
Authors: Avery, P.(1)*;Cervantes, M.L.(2);Moulton , C.(2);Hart , A.(2);
(1)St Marks Hospital and Academic Institute, Inflammatory Bowel Disease, London, United Kingdom;(2)St Marks National Bowel Hospital and Academic Institute, Inflammatory Bowel Disease, London, United Kingdom;
P1026: Rectal stump surveillance in the IBD populationECCO'25Year: 2025
Authors: Clark, J.(1)*;de Silva, S.(1);King, D.(1);
(1)The Dudley Group NHS Foundation Trust, Gastroenterology, Dudley, United Kingdom;